Attorney General for the US State of Kentucky, Daniel Cameron, announced that Kentucky will allocate $42 million for psychedelic research, specifically ibogaine for opioid addiction.
High-ranking Kentucky officials, alongside several military veterans, family members, and members of the Veteran Mental Health Leadership Coalition, held a press conference at Camp Nelson today May 31st to announce a novel approach to combating the state’s long-standing addiction crisis.
As reported in Marijuana Moment: “several military veterans and family members participated in the Kentucky Opioid Abatement Advisory Commission event alongside the state official, sharing information and anecdotes about ibogaine, which has been credited for helping people overcome substance misuse disorders when traditional therapies have failed.”
The money will be taken from the Opioid Settlement Funds
and allocated over seven years.
While ibogaine has documented effectiveness in combating addiction, it is the psychedelic with the most potential for physical side effects, including heart issues. Let’s see how the allocated funds will advance ibogaine research or if they’ll be used for research into other psychedelics as well.